801 related articles for article (PubMed ID: 11223671)
1. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
3. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.
Crawford ED; Leewansangtong S; Goktas S; Holthaus K; Baier M
Prostate; 1999 Mar; 38(4):296-302. PubMed ID: 10075009
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
5. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
6. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.
Richie JP; Catalona WJ; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; deKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
Urology; 1993 Oct; 42(4):365-74. PubMed ID: 7692657
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
8. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council.
Crawford ED; DeAntoni EP; Etzioni R; Schaefer VC; Olson RM; Ross CA
Urology; 1996 Jun; 47(6):863-9. PubMed ID: 8677578
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
[TBL] [Abstract][Full Text] [Related]
12. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Thakur V; Singh PP; Talwar M; Mukherjee U
Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
14. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
[TBL] [Abstract][Full Text] [Related]
16. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
17. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
18. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.
Catalona WJ; Partin AW; Finlay JA; Chan DW; Rittenhouse HG; Wolfert RL; Woodrum DL
Urology; 1999 Aug; 54(2):220-4. PubMed ID: 10443714
[TBL] [Abstract][Full Text] [Related]
19. [Yield of ultrasonography-guided transrectal biopsy in the diagnosis of carcinoma of the prostate].
Fernández González I; Ruiz Rubio JL; Llorente Abarca C; Aramburu González JA; Montes Díaz MJ; Herrero Payo A; Sánchez Sánchez E; Berenguer Sánchez A
Arch Esp Urol; 1995; 48(6):587-94. PubMed ID: 7544968
[TBL] [Abstract][Full Text] [Related]
20. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
